DURECT Corporation

4.46-0.0700-1.55%Vol 8.58K1Y Perf 614.62%
Mar 24th, 2023 11:10 DELAYED
BID4.44 ASK4.48
Open4.52 Previous Close4.53
Pre-Market- After-Market-
 - -%  - -
Target Price
34.67 
Analyst Rating
Strong Buy 1.00
Potential %
684.39 
Finscreener Ranking
★★★+     51.04
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
★+     44.56
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
★+     41.06
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
19.82 
Earnings Rating
Sell
Market Cap109.20M 
Earnings Date
3rd May 2023
Alpha-0.00 Standard Deviation0.26
Beta1.46 

Today's Price Range

4.424.52

52W Range

3.179.70

5 Year PE Ratio Range

-87.00-8.70

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
-2.58%
1 Month
-6.02%
3 Months
24.11%
6 Months
791.56%
1 Year
614.62%
3 Years
223.57%
5 Years
102.23%
10 Years
238.06%

TickerPriceChg.Chg.%
DRRX4.46-0.0700-1.55
AAPL158.68-0.2500-0.16
GOOG105.56-0.7000-0.66
MSFT278.630.97000.35
XOM101.23-2.1850-2.11
WFC35.41-1.2000-3.28
JNJ151.150.02000.01
FB196.640.99000.51
GE91.00-0.5900-0.64
JPM123.62-3.2200-2.54
 
ProfitabilityValueIndustryS&P 500US Markets
91.60
-127.20
-125.90
-74.60
-2.29
RevenueValueIndustryS&P 500US Markets
15.97M
0.70
-12.98
-7.38
Earnings HistoryEstimateReportedSurprise %
Q04 2022-0.53-0.4613.21
Q03 2022-0.10-0.100.00
Q02 2022-0.40-0.50-25.00
Q01 2022-0.50-0.500.00
Q04 2021-0.50-0.3040.00
Q03 2021-0.40-0.400.00
Q02 2021-0.04-0.040.00
Q01 2021-0.05-0.050.00
Earnings Per EndEstimateRevision %Trend
12/2022 QR-0.53-6.00Negative
12/2022 FY-1.62-5.88Negative
3/2023 QR-0.54-8.00Negative
12/2023 FY-1.71-4.91Negative
Next Report Date3rd May 2023
Estimated EPS Next Report-0.50
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume8.58K
Shares Outstanding24.48K
Shares Float198.08M
Trades Count83
Dollar Volume38.45K
Avg. Volume79.89K
Avg. Weekly Volume69.19K
Avg. Monthly Volume83.08K
Avg. Quarterly Volume87.39K

DURECT Corporation (NASDAQ: DRRX) stock closed at 4.53 per share at the end of the most recent trading day (a -1.09% change compared to the prior day closing price) with a volume of 67.48K shares and market capitalization of 109.20M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 95 people. DURECT Corporation CEO is James E. Brown.

The one-year performance of DURECT Corporation stock is 614.62%, while year-to-date (YTD) performance is 30.92%. DRRX stock has a five-year performance of 102.23%. Its 52-week range is between 3.165 and 9.70001, which gives DRRX stock a 52-week price range ratio of 19.82%

DURECT Corporation currently has a PE ratio of -4.00, a price-to-book (PB) ratio of 3.68, a price-to-sale (PS) ratio of 8.49, a price to cashflow ratio of 288.60, a PEG ratio of 2.32, a ROA of -42.09%, a ROC of -40.96% and a ROE of -71.55%. The company’s profit margin is -2.29%, its EBITDA margin is -125.90%, and its revenue ttm is $15.97 Million , which makes it $0.70 revenue per share.

Of the last four earnings reports from DURECT Corporation, there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.50 for the next earnings report. DURECT Corporation’s next earnings report date is 03rd May 2023.

The consensus rating of Wall Street analysts for DURECT Corporation is Strong Buy (1), with a target price of $34.67, which is +684.39% compared to the current price. The earnings rating for DURECT Corporation stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

DURECT Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

DURECT Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 17.16, ATR14 : 0.32, CCI20 : -120.17, Chaikin Money Flow : -0.67, MACD : -0.19, Money Flow Index : 22.43, ROC : -4.63, RSI : 35.30, STOCH (14,3) : 11.29, STOCH RSI : 0.00, UO : 19.60, Williams %R : -88.71), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of DURECT Corporation in the last 12-months were: Gail J. Maderis (Buy at a value of $117 142), Gail M. Farfel (Buy at a value of $31 546), Judith J. Robertson (Buy at a value of $102 391), Mohammad Azab (Buy at a value of $18 013)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

DURECT Corporation

Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, Remoxy, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the United States.

CEO: James E. Brown

Telephone: +1 408 777-1417

Address: 10260 Bubb Road, Cupertino 95014, CA, US

Number of employees: 95

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

58%42%

Bearish Bullish

55%45%

Bearish Bullish

54%46%

TipRanks News for DRRX


News

Stocktwits